Letter From The Editor

Ever since we were at the ADA meeting in Boston, there has been a lot of buzz about the artificial pancreas and how great it will be. We have even provided you with exclusive interviews with the lead researchers. When we talk to prescribers and thought leaders, we often hear …

This week, the editorial staff was assigned the task of reviewing our Homerun slides. We have so many in the archives that we had to split them up just to get them all covered. While looking at them, one of our production editors found a great 3-slide series on SGLT-2 …

  Today I got to see a referral in an Endo’s office. The patient had been referred by the primary care physician because he was on high dose Lantus and not in control. I asked my intern what she recommended and the suggestion came back meal-time insulin, but the patient …

If you get diabetes when you are 60 years old, the odds of developing kidney disease in your lifetime is low. However, if you are diagnosed when you are in your 30s or 40s, the risk is increased, and the likelihood of needing dialysis is greatly increased. This week, we …

The drug reps for DPP-4 inhibitors, GLP-1 agonists, and various insulins have been having a field day talking to prescribers about the possible cardiovascular effects of SGLT-2 inhibitors. This along with the relatively small risk of UTI’s has possibly caused some of our readers to shy away from the whole …

Often when I see a patient who has started on basal insulin, they seem to do okay. But as the prescriber starts to increase the basal dose to gain A1c control, the patient frequently gain weight and that can increase non-adherence to medications. These patients have been fighting their weight …

Last Monday night I was delivering a CE on MTM and Med Errors to a group of pharmacists in Tampa. As I was delving into the reasons for MTM (Medication Therapy Management), I was enlightening the younger pharmacists on ways that our profession has changed over the past 30 years. One …

Charcot neuroarthropathy is a serious and poorly understood condition associated with rapid destruction of bones and joints, and resulting in bone fragmentation. It is almost as if the foot implodes for no reason. Patients who deteriorate to that severe state are often those who have no idea what is happening …

Our good friend David Kliff at Diabetes Investor has had diabetes for many years. He has been watching trends in the diabetes business for a long time and has an unique perspective on the business of diabetes that we often don’t see. He has spent a lot of time lately …

Over the past 15 years, Steve and I have read many a study, article, or abstract on curing type 1 diabetes. Although many of these have shown great promise and have had some serious backing from large companies and universities, none of them have ever panned out. A couple of …